This week in retina: May 13-May 19

An end-of-week review of retina news and stories from May 13 to May 20.

This week, Modern Retina™ published interviews from ARVO and Retina World Congress.

Karl Csaky, MD, presented at Retina World Congress, where he indicated that therapies in the pipeline for the treatment of geographic atrophy (GA) should also strive to preserve central retinal tissue as well as decrease the rate of GA expansion. Meanwhile, at Retina Unplugged at Retina World Congress, Nancy Lurker, CEO of EyePoint Pharmaceuticals, discussed how EYP-1901 may usher in a new era of treat-to-maintain anti-VEGF therapies.

At ARVO, Allen C. Ho, MD, presented Phase 1/2a data for RG6501 (OpRegen), which is a retinal pgment epithelium cell transplant therapy currently being developed for the treatment of dry AMD.

Back in the clinic, MacuLogix achieves the milestone of 1 million dark adaptation tests for the detection of AMD. Impaired dark adaptation as measured by AdaptDx technology is 90% specific and sensitive to the presence of AMD.

Tissue preservation should be considered as endpoint for geographic atrophy therapies

At Retina World Congress 2022, Karl Csaky, MD, presented a talk entitled, “Interpreting Reported GA Treatment Effects to Patient Care: Concept of Tissue Preservation.” He discussed how far research in geographic atrophy has come since he embarked on a project to determine provable endpoints for geographic atrophy (GA) in 2006 and 2007. Now that treatments in the pipeline are aiming to decrease the rate of GA expansion—the endpoint Dr. Csaky and Dr. Ferris identified in their research—he doubles down on the importance of preserving the central retinal tissue.

Watch the video

Cell therapy trial may lead to treatment for dry AMD, geographic atrophy

At ARVO 2022, Allen C. Ho, MD, FACS, presented Phase 1/2a data RG6501 (OpRegen), a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD). His presentation, entitled, “Safety and Efficacy of a Phase 1/2a Clinical Trial of Transplanted Allogeneic Retinal Pigmented Epithelium (RPE, OpRegen) Cells in Advanced Dry Age-Related Macular Degeneration (AMD),” detailed the full results of the trial, which met its primary endpoints and will be moving onto the next phase of research.

Watch the interview

EYP-1901 introduces treat-to-maintain paradigm for anti-VEGF therapy

During the Retina Unplugged panel at Retina World Congress, Nancy Luker presented on new pathways in retinal diseases. She outlined how EYP-1901, EyePoint Pharmaceuticals’ candidate for the new treat-to-maintain paradigm they hope to begin. EYP-1901 combines vorolanib, a tyrosine kinase inhibitor anti-VEGF, with a bioerodible retinal implant (Durasert, EyePointPharmaceuticals).

Watch the video

MacuLogix crosses threshold of 1 million dark adaption tests

MacuLogix Inc., which offers eye care professionals the instrument, tools and education to diagnose and monitor patients with age-related macular degeneration (AMD), announced this week that more than 1 million of its dark adaptation tests have been performed using either the company’s original AdaptDx or the head-mounted AdaptDx Pro guided by Theia.

According to a news release from the company, both devices use the same proprietary technology to efficiently measure dark adaptation speed, which is used by doctors to identify and monitor AMD.

According to Julie Rodman, OD, MS, FAAO, a professor at NOVA Southeastern University, impaired dark adaptation is the earliest biomarker of AMD.

“Often manifested as night vision problems, this functional impairment becomes apparent years before drusen are visible,” she said in the news release. “In fact, many optometrists are now testing dark adaptation for every patient over age 50 as part of their standard of care.”

Impaired dark adaptation as measured by AdaptDx technology is 90% specific and sensitive to the presence of AMD.

Learn more